🔎 Trials Near Me

Home › Atrial Fibrillation › NCT06308094

320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.

Recruiting

Who can join

Ages 21 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Patients must be at least 21 years old at the time of enrollment.
* Patients must be able to give informed consent.
* Patients with symptomatic paroxysmal/persistent atrial fibrillation (AF).
* Eligible patients must be determined to be suitable candidates for ablation to treat AF by their cardiologist and/or electrophysiologists regardless of this protocol.
* Patients are scheduled to have a pre-procedure cardiac CT upon the discretion of their electrophysiologists

Exclusion Criteria:

* Known allergy to iodinated contrast media.
* Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula).
* Patients with a positive urine or serum pregnancy test will be excluded from this study.
* Patients with heart transplantation.
* Patients with polymorphic ventricular tachycardia (VT) or presenting in electrical storm.
* Presence of any other history or condition that the investigator feels would be problematic.
* Patient with iodinated contrast administration for other reason 24 hours prior to investigational CT.
* Patients who have a heart pacemaker, metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, mechanical heart valves and prosthetics that contain metal.
* Patients with severe claustrophobia.

About the study

This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment strategies.

What is being tested

Sponsor: Johns Hopkins University · Participants: 100 · Started: Apr 10, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06308094

Locations in the U.S.

MarylandJohns Hopkins Hospital, Baltimore

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.